research Hidradenitis suppurativa
Antiandrogen therapy may be beneficial for women with hidradenitis suppurativa.
Search
for
Sort by
Research
240-270 / 1000+ results research ChemInform Abstract: Discovery of a Novel Hybrid from Finasteride and Epristeride as 5α‐Reductase Inhibitor.
A new compound may effectively inhibit the enzyme linked to BPH and hair loss.
research Triple Hormonal Blockade (ADT3): A Patient’s Perspective
Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
research 15-Hydroxyprostaglandin Dehydrogenase Inhibitor Restores Endothelial Function Under Dihydrotestosterone-Induced Stress in Human Dermal Microvascular Endothelial Cells
DPP may help hair regrowth by improving blood vessel function under stress.
research Theoretical evaluation of interaction of some dibenzo derivatives on both androgen receptor and 5α-reductase enzyme
Certain Dibenzo derivatives may help treat prostate cancer.
research Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review
Dutasteride works better than finasteride for hair loss and has mild, reversible side effects.
research Evaluation of the therapeutic effects of AGA drugs by measuring finasteride, dutasteride, and dihydrotestosterone in hair
Finasteride and dutasteride effectively reduce DHT in hair, which may help evaluate their treatment success for hair loss.
research Dihydrotestosterone and 5α-Reductase
Dihydrotestosterone and 5α-Reductase play a role in hair loss and prostate health, and finasteride can increase hair growth in men without affecting sperm production, but it doesn't work for postmenopausal women with hair loss.
research Computational Evaluation of Dibenzo Compounds as Potential Dual Inhibitors of Androgen Receptor and 5α-Reductase
Some dibenzo compounds might help treat cancer with fewer side effects.
research Finasteride/spironolactone
research Significance of RU58841 as a therapeutic agent effecting androgen receptor molecular interactions in human hair follicles.
RU58841, a substance from France, can potentially block the effects of hormones that cause hair loss and excessive hair growth, performing better than a similar substance, cyproterone acetate.
research Faculty Opinions recommendation of A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
Dutasteride 0.5mg was found to be more effective than finasteride 1mg in treating male pattern hair loss, with similar side effects.
research Efficacy and tolerability of HDMHG0401-10 in Patients with Androgenetic Alopecia: A Randomized Double-blind Placebo-controlled Trial
HDMHG0401-10 treatment significantly improved hair count and was better than a placebo in reducing hair loss in men with hereditary hair loss, with no major side effects.
research Effect of Testosterone Supplementation With and Without a Dual 5α-Reductase Inhibitor on Fat-Free Mass in Men With Suppressed Testosterone Production
Testosterone's muscle-building effects do not require its conversion to DHT.
research Caffeic acid N-[3,5-bis(trifluoromethyl)phenyl] amide as a non-steroidal inhibitor for steroid 5α-reductase type 1 using a human keratinocyte cell-based assay and molecular dynamics
Compound 4 is a promising treatment for hair loss with low toxicity.
research Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride
Dutasteride helps hair growth in those unresponsive to finasteride, but may cause more sexual dysfunction.
research Clinical relevance of testosterone and dihydrotestosterone metabolism in women
Testosterone and dihydrotestosterone play a role in women's health issues like excess hair and baldness, and treatments blocking these hormones may help.
research Dutasteride
Dutasteride may become the top choice for treating hair loss.
research Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia
LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
research Steroid 17β-hydroxysteroid dehydrogenase deficiency in man: An inherited form of male pseudohermaphroditism
Affected males are born with ambiguous genitalia, raised as females, but develop male traits at puberty due to enzyme deficiency.
research A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α-reductase inhibitors GI198745 and finasteride
Both drugs lower DHT levels, with GI198745 being more effective.
research ANTIANDROGEN AND HORMONAL TREATMENT OF ACNE
Certain hormone treatments can improve acne and related conditions in women.
research Discovery and Clinical Development of Dutasteride, a Potent Dual 5α- Reductase Inhibitor
Dutasteride effectively treats benign prostatic hyperplasia and may reduce prostate cancer risk.
research Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase.
Dutasteride effectively treats enlarged prostate with manageable side effects.
research An overview on 5α-reductase inhibitors
5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.
research Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study
Men taking dutasteride or finasteride have a slightly higher risk of developing type 2 diabetes.
research Inhibition of 5α-reductase alters pregnane metabolism in the late pregnant mare
Inhibiting 5α-reductase increases progesterone levels in late pregnant mares.
research The safety of 52 weeks of oral DHEA therapy for postmenopausal women
Taking DHEA for a year is generally safe for postmenopausal women but may cause acne and more facial hair without improving metabolism or aging.
research Dihydrotestosterone Stimulates 5a-Reductase Activity in Pubic Skin Fibroblasts*
Dihydrotestosterone increases the activity of an enzyme in pubic skin cells that converts testosterone to dihydrotestosterone.
research Synthesis and structure–activity studies of side-chain derivatized arylhydantoins for investigation as androgen receptor radioligands
The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.